<DOC>
	<DOCNO>NCT00388895</DOCNO>
	<brief_summary>% positive Ph LLA RC alter Glivec induction chemotherapy treatment</brief_summary>
	<brief_title>Glivec Ph Positive Lymphoblastic Leukemia</brief_title>
	<detailed_description>Pilot phase II clinical trial , prospective , multicentric open</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>New diagnosis LLA Ph+ ( BCR/ABL ) patient â‰¤ 65 year old Fertile age woman must pregnancy test 7 day previous begin clinical trial medication Performance status 02 ( Appendix B ) ; Is allow performance status &gt; 2 LLA Patients without organ alteration : hepatic function : global bilirubin , AST , ALT , gammaGT alkaline phosphatase less 2 time LSN ; renal function : Creatinine &lt; 1,5 mg/dl Clearance creatinine &gt; 60 ml/min ; anormal renal function cause LLA ; normal heart function ( Appendix B ) : FEV &gt; 50 % ; No Chronic respiratory illness . If anormal value secondary experimental illness investigator decide patient include clinical trial . Negative HIV serology Written , oral witness inform consent . In patient &lt; 18 year old must sign write legal representative inform consent . No experimental chemotherapy experimental treatment . Allowed begin induction chemotherapy diagnosis confirm Ph . No major surgical process previous 14 day treatment Start . Other LLA variability Previous history coronary valvular , hypertensive cardiopathy illness Chronic hepatic illness Chronic respiratory insufficiency Renal insufficiency cause LLA Severe neurological problem cause LLA Severe affection performance status ( grade 34 OMS gradation ) cause LLA Pregnancy woman Blastic crisis LMC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Acute lymphoblastic Leukemia</keyword>
</DOC>